HPV vaccines: now that they're here, how do we maximize their benefit?

Contraception

Volumn 74, Issue 4, 2006, Pages 277-279

  Myers, Evan R ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FEMALE; FEMALE GENITAL TRACT INFECTION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; ONSET AGE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; DEVELOPING COUNTRIES; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCTIVE MEDICINE; UTERINE CERVICAL NEOPLASMS;

EID: 33748541969     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.07.001     Document Type: Editorial

References (26)

1. FDA documentation of Gardasil® approval. http://www.fda.gov/cber/products/hpvmer060806.htm
2. Association of Reproductive Health Professions press release, June 30, 2006. http://www.arhp.org/media/pressreleases/99-157.cfm
3. Mao C., Koutsky L.A., Ault K.A., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
4. Koutsky L.A., Ault K.A., Wheeler C.M., et al., for the Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
5. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
6. Harper D.M., Franco E.L., Wheeler C., et al., for the GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
7. Harper D.M., Franco E.L., Wheeler C.M., et al., for the HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
8. Manhart L.E., Holmes K.K., Koutsky L.A., et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 33 (2006) 502-508
9. Barr E. Presentation to the Advisory Committee on Immunization Practices, June 27, 2006. http://www.cdc.gov/nip/acip/slides/jun06/hpv-2-barr.pdf
10. Gibbs N. Defusing the war over the "promiscuity" vaccine. Time Magazine online. Posted June 21, 2006. http://www.time.com/time/nation/article/0,8599,1206813,00.html
11. Humiston S.G., and Rosenthal S.L. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J 24 6 Suppl (2005) S134-S140
12. Davis M.M., and Gaglia M.A. Associations of daycare and school entry vaccination requirements with varicella immunization rates. Vaccine 23 (2005) 3053-3060
13. Wilson T.R., Fishbein D.B., Ellis P.A., and Edlavitch S.A. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 37 (2005) 511-516
14. Davis K., Dickman E.D., Ferris D., and Dias J.K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 8 (2004) 188-194
15. Andersson-Ellstrom A., and Milsom I. Knowledge about the prevention of sexually transmitted diseases: a longitudinal study of young women from 16-23 years of age. Sex Transm Infect 78 (2002) 339-341
16. Mays R.M., Zimet G.D., Winston Y., Kee R., Dickes J., and Su L. Human papillomavirus, genital warts, Pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int 21 (2000) 361-374
17. Dell D.L., Chen H., Ahmad F., and Stewart D.E. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 96 (2000) 653-656
18. Borawski E.A., Trapl E.S., Lovegreen L.D., Colabianchi N., and Block T. Effectiveness of abstinence-only intervention in middle school teens. Am J Health Behav 29 (2005) 423-434
19. Aten M.J., Siegel D.M., Enaharo M., and Auinger P. Keeping middle school students abstinent: outcomes of a primary prevention intervention. J Adolesc Health 31 (2002) 70-78
20. Perrin K.K., and DeJoy S.B. Abstinence-only education: how we got here and where we're going. J Public Health Policy 24 (2003) 445-459
21. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev (2006) [Epub ahead of print]
22. Goldie S.J., Kohli M., Grima D., Weinstein M.C., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
23. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
24. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 (2003) 37-48
25. Sadler L., Saftlas A., Wang W., Exeter M., Whittaker J., and McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 291 (2004) 2100-2106
26. Winer R.L., Hughes J.P., Feng Q., O'Reilly S., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2006) 2645-2654